EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation

Yu-Nan Huang iD, Min-Yu Tsou, Pin-Hung Li iD, Jo-Ching Chen iD, Yen-Liang Liu iD, Gideon Meyerowitz-Katz iD, Tsung-Hsun Tsai, Pen-Hua Su iD

Advanced Science · 2026

DOI: 10.1002/advs.202518813 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Yu-Nan Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetics and Endocrinology, Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, 402306, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taiwan, Chung Shan Medical University Hospital, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Evidence on pre‐transplant metabolic therapy remains limited. We evaluated whether concurrent glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) plus sodium–glucose cotransporter 2 inhibitor (SGLT2i) use before solid‐organ transplantation was associated with post‐transplant outcomes in adults with obesity and type 2 diabetes. A target trial is emulated using de‐identified electronic health records from TriNetX US. Dual therapy is compared with GLP‐1 RA, SGLT2i, and usual care using 1:1 propensity‐score matching. The primary outcome is all‐cause mortality at 12 months; kidney graft failure, rejection, complications, and infections are secondary. Sensitivity analyses included the global network, landmark, extensions at 24 and 36 months. Three matched cohorts are constructed, dual versus GLP‐1 RA (n = 4718 pairs), dual versus SGLT2i (n = 4282), and dual versus usual care (n = 3787). At 12 months, dual therapy is associated with lower mortality versus GLP‐1 RA (hazard ratio [HR] 0.69, 95% confidence interval [CI] 0.57–0.85), SGLT2i (0.59, 0.48–0.72), and usual care (0.52, 0.43–0.64). Infection endpoints are neutral or lower. Estimates are consistent across sensitivity analyses. In transplant candidates with obesity and type 2 diabetes, pre‐transplant GLP‐1 RA+SGLT2i use is associated with lower mortality than monotherapy or usual care. Prospective evaluation is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsObesityOrgan TransplantationHumansMaleFemaleMiddle AgedAgedAdultTreatment OutcomeHypoglycemic Agents

Stichwörter der Autor:innen

GLP‐1 receptor agonistsSGLT2 inhibitorsorgan transplantationpre‐transplant optimizationtype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Genetics and Endocrinology, Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, 402306, Taiwan.
  • School of Medicine, Chung Shan Medical University, Taichung, 402306, Taiwan.
  • Cancer Biology and Precision Therapeutics Center, China Medical University, Taichung, 406040, Taiwan.
  • Master Program for Biomedical Engineering, China Medical University, Taichung, 406040, Taiwan.
  • School of Health and Society, University of Wollongong, Wollongong, 2522, Australia.
  • Division of Urology, Department of Surgery, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, 427213, Taiwan.

ORCID-Profile: Yu-Nan Huang, Pin-Hung Li, Jo-Ching Chen, Yen-Liang Liu, Gideon Meyerowitz-Katz, Pen-Hua Su

Förderung

  • National Science and Technology Council, Taiwan
  • Chung Shan Medical University Hospital
  • National Science and Technology Council

Zitieren

APA

Huang, Y. N., Tsou, M. Y., Li, P. H., Chen, J. C., Liu, Y. L., Meyerowitz-Katz, G., Tsai, T. H., & Su, P. H. (2026). Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation. Advanced Science. https://doi.org/10.1002/advs.202518813

Vancouver

Huang YN, Tsou MY, Li PH, Chen JC, Liu YL, Meyerowitz-Katz G, et al. Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation. Advanced Science. 2026. doi:10.1002/advs.202518813

BibTeX
@article{Huang2026,
  author = {Huang, Yu-Nan and Tsou, Min-Yu and Li, Pin-Hung and Chen, Jo-Ching and Liu, Yen-Liang and Meyerowitz-Katz, Gideon and Tsai, Tsung-Hsun and Su, Pen-Hua},
  title = {Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202518813}
}
Kostenlos starten →